The legal action, spearheaded by the firm Glancy Prongay Wolke & Rotter LLP, centers on claims that Capricor Therapeutics failed to disclose critical regulatory hurdles. According to the complaint, the company modified its statistical analysis plan for the Duchenne muscular dystrophy treatment without prior FDA agreement. Plaintiffs contend that these undisclosed changes created significant risks regarding the drug's efficacy and its eventual path to regulatory approval.
In section Releases
Investors Face Deadline in Capricor Therapeutics Securities Lawsuit
Investors who incurred losses from Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, have until September 28 to petition the court to act as lead plaintiff. The class action suit alleges the company misled shareholders regarding its clinical data analysis for the drug Deramiocel.
Investors who purchased shares during the specified period were allegedly misled by corporate statements that lacked a reasonable basis. While the case is currently in its early stages and no class has been certified, those affected must move the court by the September 28 deadline to serve as a lead plaintiff. Investors retain the option to choose their own counsel or remain absent class members, though the firm emphasizes that past litigation successes do not guarantee future results.
Comments (0)
No comments yet. Be the first!